LifeMD, Inc.
NASDAQ•LFMD
CEO: Mr. Justin Schreiber
セクター: Healthcare
業種: Medical - Pharmaceuticals
上場日: 2008-01-29
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.
連絡先情報
時価総額
$144.41M
PER (TTM)
-30.1
466.4
配当利回り
--
52週高値
$15.84
52週安値
$2.56
52週レンジ
順位64Top 94.9%
1.7
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q3 2025 データ
売上高
$60.17M+12.95%
直近4四半期の推移
EPS
-$0.10-29.07%
直近4四半期の推移
フリーCF
$6.42M+136.93%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Telehealth Revenue Strong Growth Telehealth revenue reached $147.2M for nine months, marking a 34% increase compared to prior year period.
Total Revenue Increased 25% Total net revenues were $187.0M for nine months ended September 30, 2025, showing 25% growth.
Gross Profit Margin Improvement Gross profit grew 9% to $52.8M for the quarter, supported by increased telehealth subscription demand.
リスク要因
Working Capital Deficit Persists Working capital deficit reached $(15.6M) as of September 30, 2025, driven by cash usage for debt repayment.
Significant Legal Contingencies Multiple shareholder class action and derivative complaints filed in late 2025 regarding business conduct and disclosures.
Accumulated Deficit Widens Accumulated deficit reached $(247.8M) as of September 30, 2025, reflecting cumulative net losses since inception.
見通し
Focus on Pure-Play Telehealth Sold majority WorkSimpli interest in November 2025 to focus on scaling virtual care and pharmacy operations.
Cash Sufficient for Twelve Months Existing cash balance of $23.8M is expected to fund planned operating and capital expenditures for next 12 months.
Expanding Weight Management Access Launched GLP-1 program expansion and secured pathways for Zepbound and Ozempic access for patients.
同業比較
売上高 (TTM)
$2.76B
$424.09M
$349.88M
粗利益率 (最新四半期)
100.0%
93.9%
92.9%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| CERS | $370.73M | -23.5 | -26.4% | 43.7% |
| RXST | $317.34M | -8.1 | -14.0% | 3.5% |
| SCPH | $302.20M | -3.3 | -2086.1% | 65.4% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-2.2%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい
深度リサーチ
次回決算:2026年3月9日
EPS:-$0.01
|売上高:$48.57M
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし